Upgrade for Complete Access See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
McKesson
Dow
McKinsey
Colorcon

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 6,537,750

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 6,537,750
Title: Plant fatty acid desaturase promoters
Abstract:Fatty acid desaturase 5\' regulatory elements are described, as well as nucleic acid constructs and transgenic plants that include these regulatory elements. Also described are fatty acid desaturase 3\' untranslated regions.
Inventor(s): Shorrosh; Basil S. (Fort Collins, CO)
Assignee: Cargill Incorporated (Wayzata, MN)
Application Number:09/366,715
Patent Claims:1. An isolated nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4; (b) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5; (c) a nucleic acid molecule having the nucleotide sequence of nucleotides 5113 to 5796 of SEQ ID NO:4; (d) a nucleic acid molecule having the nucleotide sequence of nucleotides 3197 to 3867 of SEQ ID NO:5; (e) a nucleic acid molecule having a nucleotide sequence complementary to the nucleic acid molecule of (a), (b), (c), or (d); and (f) a nucleic acid molecule at least 100 nucleotides in length and having at least 86% sequence identity to said nucleic acid molecule of (a), (b), (c), (d), or (e), wherein said nucleic acid molecule is capable of promoting expression of a heterologous nucleic acid molecule in a transformed plant cell.

2. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule of part (f) is at least 400 nucleotides in length.

3. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule of part (f) is at least 600 nucleotides in length.

4. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule of part (f) is at least 800 nucleotides in length.

5. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule of part (f) is at least 90% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

6. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule of part (f) is at least 95% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

7. The isolated nucleic acid fragment of claim 1, wherein said nucleic acid fragment comprises nucleotides 5113 to 5796 of SEQ ID NO:4.

8. The isolated nucleic acid fragment of claim 1, wherein said nucleic acid fragment comprises nucleotides 3197 to 3867 of SEQ ID NO:5.

9. The isolated nucleic acid molecule of claim 1, said nucleic acid having the nucleotide sequence of SEQ ID NO:4.

10. The isolated nucleic acid molecule of claim 1, said nucleic acid having the nucleotide sequence of SEQ ID NO:5.

11. A nucleic acid construct comprising a first nucleic acid molecule operably linked to a second nucleic acid molecule heterologous to said first nucleic acid molecule, said first nucleic acid molecule comprising a regulatory element of a fatty acid desaturase gene, wherein said regulatory element comprises a nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4; (b) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5; (c) a nucleic acid molecule having the nucleotide sequence of nucleotides 5113 to 5796 of SEQ ID NO:4; (d) a nucleic acid molecule having a nucleotide sequence of nucleotides 3197 to 3867 of SEQ ID NO:5; (e) a nucleic acid molecule having a nucleotide sequence complementary to the nucleic acid molecule of (a), (b), (c), or (d); and (f) a nucleic acid molecule at least 100 nucleotides in length and having at least 86% sequence identity to said nucleic acid molecule of (a), (b), (c), (cl), or (c); and wherein said first nucleic acid molecule promotes expression of said second nucleic acid molecule.

12. The nucleic acid construct of claim 11, said construct further comprising a third nucleic acid molecule operably linked to the 3' end of said second nucleic acid molecule, wherein said third nucleic acid molecule comprises a3' untranslated region of a fatty acid desaturase gene, wherein said 3' untranslated region is located 3' of said fatty acid desaturase gene in a naturally occurring genome.

13. The nucleic acid construct of claim 12, wherein said third nucleic acid molecule is selected from the group consisting of: (a) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:6; (b) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:7; (c) a nucleic acid molecule having the nucleotide sequence of nucleotides 1-894 of SEQ ID NO:6; (d) a nucleic acid molecule having the nucleotide sequence of nucleotides 1-817 of SEQ ID NO:7; (e) a nucleic acid molecule at least 100 nucleotides in length and having at least 86% sequence identity to the nucleic acid molecule of (c) or (d); and (f) a nucleic acid nolecule having a nucleotide sequence that is complementary to the nucleic acid molecule of (a), (b)), (c), (d), or (e).

14. The nucleic acid construct of claim 11, said construct further comprising a fourth nucleic acid molecule operably linking said first nucleic acid molecule to said second nucleic acid molecule, wherein said fourth nucleic acid molecule is a transit peptide.

15. The nucleic acid construct of claim 11, said construct further comprising a fourth nucleic acid molecule operably linking said first nucleic acid molecule to said second nucleic acid molecule, wherein said fourth nucleic acid molecule is an intron.

16. The nucleic acid construct of claim 11, wherein said heterologous nucleic acid sequence encodes a ribozyme.

17. The nucleic acid construct of claim 11, wherein said heterologous nucleic acid sequence encodes a polypeptide.

18. The nucleic acid construct of claim 17, wherein said polypeptide confers herbicide resistance.

19. The nucleic acid construct of claim 11, wherein said nucleic acid molecule of part (f) is at least 400 nucleotides in length.

20. The nucleic acid construct of claim 11, wherein said nucleic acid molecule of part (f) is at least 600nucleotides in length.

21. The nucleic acid construct of claim 11, wherein said nucleic acid molecule of part (f) is at least 800 nucleotides in length.

22. The nucleic acid construct of claim 11, wherein said nucleic acid molecule of part (f) is at least 90% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

23. The nucleic acid construct of claim 11, wherein said nucleic acid molecule of part (f) is at least 95% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

24. A transformed plant cell, said cell containing a nucleic acid construct comprising a regulatory element of a fatty acid desaturase gene operably linked to a heterologous nucleic acid, wherein said regulatory element promotes expression of said heterologous nucleic acid, and wherein said regulatory element comprises a nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4; (b) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5; (c) a nucleic acid molecule having the nucleotide sequence of nucleotides 5113 to 5796 of SEQ ID NO:4; (d) a nucleic acid molecule having the nucleotide sequence of nucleotides 3197 to 3867 of SEQ ID NO:5; (e) a nucleic acid molecule having a nucleotide sequence complementary to the nucleic acid molecule of (a), (b), (c), or (d); and (f) a nucleic acid molecule at least 100 nucleotides in length and having at least 86% sequence identity to said nucleic acid molecule of (a), (b), (c), (d), or (e).

25. The transformed plant cell of claim 24, wherein said nucleic acid molecule of part (f) is at least 400 nucleotides in length.

26. The transformed plant cell of claim 24, wherein said nucleic acid molecule of part (f) is at least 600 nucleotides in length.

27. The transformed plant cell of claim 24, wherein said nucleic acid molecule of part (f) is at least 800 nucleotides in length.

28. The transformed plant cell of claim 24, wherein said nucleic acid molecule of part (f) is at least 90% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

29. The transformed plant cell of claim 24, wherein said nucleic acid molecule of part (f) is at least 95% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

30. The transformed plant cell of claim 24, said nuclei acid molecule having the nucleotide sequence SEQ ID NO:4.

31. The transformed plant cell of claim 24, said nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5.

32. A transgenic plant comprising at least one nucleic acid construct, said construct comprising a regulatory element of a fatty acid desaturase gene operably linked to a heterologous nucleic acid, wherein said regulatory element promotes expression of said heterologous nucleic acid, and wherein said regulatory element comprises a nucleic acid molecule selected from the group consisting of: (a) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4; (b) a nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5; (c) a nucleic acid molecule having the nucleotide sequence of nucleotides 5113 to 5796 of SEQ ID NO:4; (d) a nucleic acid molecule having the nucleotide sequence of nuclcotides 3197 to 3867 of SEQ ID NO:5; (e) a nucleic acid molecule having a nucleotide sequence complementary to the nucleic acid molecule of (a), (b), (c), or (d); and (f) a nucleic acid molecule at least 100 nucleotides in length and having at least 86% sequence identity to said nucleic acid molecule of (a, (b), (c), (d), or (e).

33. The transgenic plant of claim 32, wherein said plant is a dicot.

34. The transgenic plant of claim 33, wherein said dicot is alfalfa, soybean, rapeseed, or sunflower.

35. The transgenic plant of claim 32, wherein said plant is a monocot.

36. The transgenic plant of claim 35, wherein said monocot is corn, wheat, rye, rice, or sorghum.

37. A seed from the transgenic plant of claim 32.

38. The transgenic plant of claim 32, wherein said nucleic acid molecule of part (f) is least 400 nucleotides in length.

39. The transgenic plant of claim 32, wherein said nucleic acid molecule of part (f) is at least 600 nucleotides in length.

40. The transgenic plant of claim 32, wherein said nucleic acid molecule of part (f) is at least 800 nucleotides in length.

41. The transgenic plant of claim 32, wherein said nucleic acid molecule of part (f) is at least 90% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

42. The transgenic plant of claim 32, wherein said nucleic acid molecule of part (f) is at least 95% identical to said nucleic acid molecule of (a), (b), (c), (d), or (e).

43. The transgenic plant of claim 32, said nucleic acid molecule having the nucleotide sequence of SEQ ID NO:4.

44. The transgenic plan of claim 32, said nucleic acid molecule having the nucleotide sequence of SEQ ID NO:5.

45. Plasmid pMB102, represented by ATCC accession number PTA-2536.

46. Plasmid pMB103, represented by ATCC accession number PTA-2535.

47. An nucleic acid construct comprising a first nucleic acid molecule operably linked to a second nucleic acid molecule heterologous to said first nucleic acid molecule, said first nucleic acid molecule comprising a 3' untranslated region of a fatty acid desaturase gene, wherein said3' untranslated region is located3' of said fatty acid desaturase gene in a naturally occurring genome.

Details for Patent 6,537,750

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 1986-06-04 ⤷  Sign up for a Free Trial 2018-08-04
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Sign up for a Free Trial 2018-08-04
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
McKinsey
Dow
Mallinckrodt
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.